B
Bankole A. Johnson
Researcher at University of Virginia
Publications - 146
Citations - 9246
Bankole A. Johnson is an academic researcher from University of Virginia. The author has contributed to research in topics: Alcohol dependence & Topiramate. The author has an hindex of 48, co-authored 145 publications receiving 8729 citations. Previous affiliations of Bankole A. Johnson include University of Texas Health Science Center at Houston & University of Texas at San Antonio.
Papers
More filters
Journal ArticleDOI
Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence: The COMBINE Study: A Randomized Controlled Trial
Raymond F. Anton,Stephanie S. O'Malley,Domenic A. Ciraulo,Ron A. Cisler,David Couper,Dennis M. Donovan,David R. Gastfriend,James D. Hosking,Bankole A. Johnson,Joseph S. LoCastro,Richard Longabaugh,Barbara J. Mason,Margaret E. Mattson,William R. Miller,Helen M. Pettinati,Carrie L. Randall,Robert M. Swift,Roger D. Weiss,Lauren D. Williams,Allen Zweben +19 more
TL;DR: Patients receiving medical management with naltrexone, CBI, or both fared better on drinking outcomes, whereas acamprosate showed no evidence of efficacy, with or without CBI.
Journal ArticleDOI
Oral topiramate for treatment of alcohol dependence: a randomised controlled trial
Bankole A. Johnson,Nassima Ait-Daoud,Charles L. Bowden,Carlo C. DiClemente,John D. Roache,Kevin Lawson,Martin A. Javors,Jennie Z. Ma +7 more
TL;DR: Topiramate (up to 300 mg per day) is more efficacious than placebo as an adjunct to standardised medication compliance management in treatment of alcohol dependence.
Journal ArticleDOI
Topiramate for Treating Alcohol Dependence: A Randomized Controlled Trial
Bankole A. Johnson,Norman E. Rosenthal,Julie A. Capece,Frank Wiegand,Lian Mao,Karen Beyers,Amy McKay,Nassima Ait-Daoud,Raymond F. Anton,Domenic A. Ciraulo,Henry R. Kranzler,Karl Mann,Stephanie S. O'Malley,Robert M. Swift +13 more
TL;DR: Topiramate is a promising treatment for alcohol dependence as discussed by the authors, which can improve drinking outcomes among alcohol-dependent individuals by reducing alcohol's reinforcing effects through facilitation of γ-aminobutyric acid function and inhibition of glutaminergic pathways in the corticomesolimbic system.
Journal ArticleDOI
Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial.
Bankole A. Johnson,John D. Roache,Martin A. Javors,Carlo C. DiClemente,Claude Robert Cloninger,Thomas J. Prihoda,Patrick S. Bordnick,Nassima Ait-Daoud,Julie G. Hensler +8 more
TL;DR: The results suggest that ondansetron (particularly the 4 microg/kg twice per day dosage) is an effective treatment for patients with early-onset alcoholism, presumably by ameliorating an underlying serotonergic abnormality.
Journal ArticleDOI
Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings.
TL;DR: Research continues to explore which types of alcohol-dependent individual would benefit the most from treatment with naltrexone or acamprosate and other promising medications, as well as medication combinations, for treating alcohol dependence continue to be explored.